4 completed, 2 terminated, 1 withdrawn. 4 Phase 2, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Polish Lymphoma Research Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) Acalabrutinib 2x100 MG Oral Capsule + alloSCT - Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease | Phase 2 | Completed | Polish Lymphoma Research Group | 29 | 2019-08-19 | 2025-01-16 |
| Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse Obinutuzumab - Mantle Cell Lymphoma | Phase 2 | Terminated | Polish Lymphoma Research Group | 1 | 2018-05-14 | 2023-08-16 |
| The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD Bendamustine, Gemcitabine, Dexamethasone - Hodgkin's Lymphoma | Phase 2 | Completed | Polish Lymphoma Research Group | 115 | 2017-11-06 | 2025-01-16 |
| Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas Methotrexate, Interferon Alfa-2b - Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides | Phase 4 | Terminated | Polish Lymphoma Research Group | 100 | 2014-06-01 | 2022-01-13 |
| Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) ABVD + FDG-PET/CT Scan treatment adaptation, BEACOPPesc - Hodgkin Lymphoma | Phase 3 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2013-05-01 | 2021-02-15 | |
| Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Ofatumumab, Etoposide, Ifosfamid - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Polish Lymphoma Research Group | 77 | 2011-11-01 | 2021-12-27 |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Rituximab, Cyclophosphamide, Doxorubicin - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Completed | Polish Lymphoma Research Group | 250 | 2007-02-01 | 2017-07-17 |
Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, Mantle-Cell (2) · Bronchiolitis Obliterans Syndrome (1) · Leukemia, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Neoplasm, Residual (1)
Methotrexate (2) · ABVD protocol (1) · Bendamustine Hydrochloride (1) · Clorazepate Dipotassium (1) · Cyclophosphamide (1) · Cytarabine (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Filgrastim (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Ifosfamide (1) · Interferon alpha-2 (1) · Introns (1)
Poland (6) · Denmark (1)
Sebastian Giebel, Prof. (3) · Andrzej Hellmann, Prof. (1) · Andrzej Lange, Prof. (1) · Andrzej Pluta, Prof. (1) · Berthe Aleman (1) · Ewa Chmielowska, MD, PhD (1) · Jan A Walewski, Prof. (1) · Jan M Zaucha, Prof. (1) · Jan Walewski, Prof. (1) · Krzysztof Warzocha, Prof. (1) · Maria Podolak-Dawidziak, Prof. (1) · Martin Hutchings (1)
2015 (1)